Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study

Simcock, Mathew; Blasko, Monika; Karrer, Urs; Bertisch, Barbara; Pless, Miklos; Blumer, Liisa; Vora, Samir; Robinson, J. O.; Bernasconi, Enos; Terziroli, Benedetta; Moirandat-Rytz, Sophie; Furrer, Hansjakob; Hirschel, Bernard; Vernazza, Pietro; Sendi, Pedram; Rickenbach, Martin; Bucher, H. C.; Battegay, Manuel; Koller, M. T.

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
Authors		Simcock, Mathew Blasko, Monika Karrer, Urs Bertisch, Barbara Pless, Miklos Blumer, Liisa Vora, Samir Robinson, J. O. Bernasconi, Enos Terziroli, Benedetta Moirandat-Rytz, Sophie Furrer, Hansjakob Hirschel, Bernard Vernazza, Pietro Sendi, Pedram Rickenbach, Martin Bucher, H. C. Battegay, Manuel Koller, M. T. show all authors [1 - 19]
Published in		Antiviral therapy. 2007, vol. 12, no. 6, p. 931-939
Abstract		OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma. METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain. We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database. Cox regression analyses were performed to study predictors of overall and progression-free survival. RESULTS: During a median follow up of 1.6 years, 57 patients died or progressed. Thirty-five patients stopped chemotherapy prematurely (before the sixth cycle) usually due to disease progression; these patients had a shorter median survival than those who completed six or more cycles (14 versus 28 months). Interruptions of cART decreased from 35% before chemotherapy to 5% during chemotherapy. Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]). CONCLUSIONS: Interruptions of cART were usually not induced by chemotherapy. The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.
Keywords		Adult — Anti-HIV Agents/ therapeutic use — Antineoplastic Agents/ therapeutic use — Antineoplastic Combined Chemotherapy Protocols/administration & — Dosage/ therapeutic use — Antiretroviral Therapy, Highly Active — CD4 Lymphocyte Count — Cohort Studies — Female — HIV Infections/complications/ drug therapy/mortality/virology — Hepatitis C/complications — Humans — Kaplan-Meiers Estimate — Lymphoma, AIDS-Related/complications/ drug therapy/mortality — Male — Middle Aged — Prognosis — Prospective Studies
Identifiers		PMID: 17926647
Full text		Article - Limited access to UNIGE Other version: http://www.intmedpress.com/journals/avt/abstract.cfm?id=379&pid=88
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Citation (ISO format)		SIMCOCK, Mathew et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. In: Antiviral therapy, 2007, vol. 12, n° 6, p. 931-939. https://archive-ouverte.unige.ch/unige:7583